{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T02:47:18Z","timestamp":1789267638504,"version":"build-2803163510"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T00:00:00Z","timestamp":1752796800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFE0204500"],"award-info":[{"award-number":["2023YFE0204500"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-025-03600-x","type":"journal-article","created":{"date-parts":[[2025,7,18]],"date-time":"2025-07-18T11:30:56Z","timestamp":1752838256000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Rapid diagnostic imaging and targeted immunotoxin delivery in aggressive prostate cancer using CEACAM5-specific nanobodies"],"prefix":"10.1186","volume":"23","author":[{"given":"Zhaoming","family":"Xiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingbo","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinpeng","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liuhai","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangwei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhifen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengming","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanqiao","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jigang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-Chao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,18]]},"reference":[{"issue":"4","key":"3600_CR1","doi-asserted-by":"publisher","first-page":"102096","DOI":"10.1016\/j.clgc.2024.102096","volume":"22","author":"F Paolieri","year":"2024","unstructured":"Paolieri F, et al. Front-line therapeutic strategy in metastatic hormone sensitive prostate cancer: an updated therapeutic algorithm. Clin Genitourin Cancer. 2024;22(4):102096.","journal-title":"Clin Genitourin Cancer"},{"issue":"10","key":"3600_CR2","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1093\/annonc\/mdz210","volume":"30","author":"BPS Belderbos","year":"2019","unstructured":"Belderbos BPS, et al. Novel treatment options in the management of metastatic castration-na\u00efve prostate cancer; which treatment modality to choose? Ann Oncol. 2019;30(10):1591\u2013600.","journal-title":"Ann Oncol"},{"issue":"2","key":"3600_CR3","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1903835","volume":"381","author":"ID Davis","year":"2019","unstructured":"Davis ID, et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N Engl J Med. 2019;381(2):121\u201331.","journal-title":"N Engl J Med"},{"key":"3600_CR4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.canlet.2021.06.010","volume":"519","author":"Y Yamada","year":"2021","unstructured":"Yamada Y, Beltran H. The treatment landscape of metastatic prostate cancer. Cancer Lett. 2021;519:20\u20139.","journal-title":"Cancer Lett"},{"issue":"2","key":"3600_CR5","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/bph.15300","volume":"178","author":"Y Wang","year":"2021","unstructured":"Wang Y, et al. Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it. Br J Pharmacol. 2021;178(2):239\u201361.","journal-title":"Br J Pharmacol"},{"issue":"3","key":"3600_CR6","doi-asserted-by":"publisher","first-page":"205","DOI":"10.2967\/jnmt.122.263814","volume":"50","author":"EE Parent","year":"2022","unstructured":"Parent EE, et al. (177)Lu-PSMA therapy. J Nucl Med Technol. 2022;50(3):205\u201312.","journal-title":"J Nucl Med Technol"},{"issue":"5","key":"3600_CR7","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","volume":"25","author":"L Emmett","year":"2024","unstructured":"Emmett L, et al. [(177)Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2024;25(5):563\u201371.","journal-title":"Lancet Oncol"},{"issue":"6","key":"3600_CR8","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1007\/s00262-015-1707-3","volume":"64","author":"PF Mulders","year":"2015","unstructured":"Mulders PF, et al. Targeted treatment of metastatic castration-resistant prostate cancer with sipuleucel-T immunotherapy. Cancer Immunol Immunother. 2015;64(6):655\u201363.","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"3600_CR9","doi-asserted-by":"publisher","first-page":"18","DOI":"10.5858\/arpa.2019-0124-RA","volume":"144","author":"V Manucha","year":"2020","unstructured":"Manucha V, Henegan J. Clinicopathologic diagnostic approach to aggressive variant prostate cancer. Arch Pathol Lab Med. 2020;144(1):18\u201323.","journal-title":"Arch Pathol Lab Med"},{"key":"3600_CR10","doi-asserted-by":"publisher","DOI":"10.1530\/JOE-22-0211","author":"L Brady","year":"2023","unstructured":"Brady L, Nelson PS. RISING STARS: heterogeneity and the tumor microenvironment in neuroendocrine prostate cancer. J Endocrinol. 2023. https:\/\/doi.org\/10.1530\/JOE-22-0211.","journal-title":"J Endocrinol"},{"issue":"1","key":"3600_CR11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13046-022-02255-y","volume":"41","author":"L Merkens","year":"2022","unstructured":"Merkens L, et al. Aggressive variants of prostate cancer: underlying mechanisms of neuroendocrine transdifferentiation. J Exp Clin Cancer Res. 2022;41(1):46.","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"3600_CR12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s11912-020-01003-9","volume":"23","author":"Y Yamada","year":"2021","unstructured":"Yamada Y, Beltran H. Clinical and biological features of neuroendocrine prostate cancer. Curr Oncol Rep. 2021;23(2):15.","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"3600_CR13","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/s41698-024-00599-6","volume":"8","author":"A Ajkunic","year":"2024","unstructured":"Ajkunic A, et al. Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: expression landscape and molecular correlates. NPJ Precis Oncol. 2024;8(1):104.","journal-title":"NPJ Precis Oncol"},{"issue":"19","key":"3600_CR14","doi-asserted-by":"publisher","first-page":"E4473","DOI":"10.1073\/pnas.1802354115","volume":"115","author":"JK Lee","year":"2018","unstructured":"Lee JK, et al. Systemic surfaceome profiling identifies target antigens for immune-based therapy in subtypes of advanced prostate cancer. Proc Natl Acad Sci U S A. 2018;115(19):E4473-e4482.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"3600_CR15","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1158\/1078-0432.CCR-20-3396","volume":"27","author":"DC DeLucia","year":"2021","unstructured":"DeLucia DC, et al. Regulation of CEACAM5 and therapeutic efficacy of an anti-CEACAM5-SN38 antibody-drug conjugate in neuroendocrine prostate cancer. Clin Cancer Res. 2021;27(3):759\u201374.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3600_CR16","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1530\/ERC-18-0226","volume":"26","author":"MK Bakht","year":"2018","unstructured":"Bakht MK, et al. Neuroendocrine differentiation of prostate cancer leads to PSMA suppression. Endocr Relat Cancer. 2018;26(2):131\u201346.","journal-title":"Endocr Relat Cancer"},{"issue":"7","key":"3600_CR17","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.2967\/jnumed.123.267107","volume":"65","author":"C Imberti","year":"2024","unstructured":"Imberti C, et al. CEACAM5-targeted immuno-PET in androgen receptor-negative prostate cancer. J Nucl Med. 2024;65(7):1043\u201350.","journal-title":"J Nucl Med"},{"issue":"8","key":"3600_CR18","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1007\/s00259-023-06183-7","volume":"50","author":"Y Xiao","year":"2023","unstructured":"Xiao Y, et al. Identification of a CEACAM5 targeted nanobody for positron emission tomography imaging and near-infrared fluorescence imaging of colorectal cancer. Eur J Nucl Med Mol Imaging. 2023;50(8):2305\u201318.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"3600_CR19","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1038\/s41467-022-29630-9","volume":"13","author":"JM de Gooyer","year":"2022","unstructured":"de Gooyer JM, et al. Multimodal CEA-targeted fluorescence and radioguided cytoreductive surgery for peritoneal metastases of colorectal origin. Nat Commun. 2022;13(1):2621.","journal-title":"Nat Commun"},{"issue":"22","key":"3600_CR20","doi-asserted-by":"publisher","first-page":"5934","DOI":"10.1158\/1078-0432.CCR-20-2255","volume":"26","author":"JM de Gooyer","year":"2020","unstructured":"de Gooyer JM, et al. Multimodal CEA-targeted image-guided colorectal cancer surgery using (111)In-labeled SGM-101. Clin Cancer Res. 2020;26(22):5934\u201342.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"3600_CR21","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41401-023-01200-9","volume":"45","author":"XY Zhu","year":"2024","unstructured":"Zhu XY, et al. A novel human single-domain antibody-drug conjugate targeting CEACAM5 exhibits potent in vitro and in vivo antitumor activity. Acta Pharmacol Sin. 2024;45(3):609\u201318.","journal-title":"Acta Pharmacol Sin"},{"issue":"4","key":"3600_CR22","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1016\/j.annonc.2021.12.012","volume":"33","author":"A Gazzah","year":"2022","unstructured":"Gazzah A, et al. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody-drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study. Ann Oncol. 2022;33(4):416\u201325.","journal-title":"Ann Oncol"},{"key":"3600_CR23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.canlet.2021.10.041","volume":"525","author":"DS Baek","year":"2022","unstructured":"Baek DS, et al. A highly-specific fully-human antibody and CAR-T cells targeting CD66e\/CEACAM5 are cytotoxic for CD66e-expressing cancer cells in vitro and in vivo. Cancer Lett. 2022;525:97\u2013107.","journal-title":"Cancer Lett"},{"issue":"3\u20134","key":"3600_CR24","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s10555-013-9444-6","volume":"32","author":"N Beauchemin","year":"2013","unstructured":"Beauchemin N, Arabzadeh A. Carcinoembryonic antigen-related cell adhesion molecules (CEACAMs) in cancer progression and metastasis. Cancer Metastasis Rev. 2013;32(3\u20134):643\u201371.","journal-title":"Cancer Metastasis Rev"},{"issue":"29","key":"3600_CR25","doi-asserted-by":"publisher","first-page":"3338","DOI":"10.1200\/JCO.2017.73.9011","volume":"35","author":"E Dotan","year":"2017","unstructured":"Dotan E, et al. Phase I\/II trial of labetuzumab govitecan (Anti-CEACAM5\/SN-38 Antibody-Drug Conjugate) in patients with refractory or relapsing metastatic colorectal cancer. J Clin Oncol. 2017;35(29):3338\u201346.","journal-title":"J Clin Oncol"},{"issue":"24","key":"3600_CR26","doi-asserted-by":"publisher","first-page":"6589","DOI":"10.1158\/1078-0432.CCR-19-4051","volume":"26","author":"S Decary","year":"2020","unstructured":"Decary S, et al. Preclinical activity of SAR408701: a novel anti-CEACAM5-maytansinoid antibody-drug conjugate for the treatment of CEACAM5-positive epithelial tumors. Clin Cancer Res. 2020;26(24):6589\u201399.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"3600_CR27","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1080\/13543784.2023.2249814","volume":"32","author":"T De Pauw","year":"2023","unstructured":"De Pauw T, et al. Current status and future expectations of nanobodies in oncology trials. Expert Opin Investig Drugs. 2023;32(8):705\u201321.","journal-title":"Expert Opin Investig Drugs"},{"issue":"4","key":"3600_CR28","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1517\/17425247.2016.1133583","volume":"13","author":"KB Turner","year":"2016","unstructured":"Turner KB, et al. Improving the targeting of therapeutics with single-domain antibodies. Expert Opin Drug Deliv. 2016;13(4):561\u201370.","journal-title":"Expert Opin Drug Deliv"},{"issue":"1","key":"3600_CR29","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s40824-022-00312-3","volume":"26","author":"J Ma","year":"2022","unstructured":"Ma J, et al. CDH17 nanobodies facilitate rapid imaging of gastric cancer and efficient delivery of immunotoxin. Biomater Res. 2022;26(1):64.","journal-title":"Biomater Res"},{"key":"3600_CR30","doi-asserted-by":"publisher","first-page":"0041","DOI":"10.34133\/bmr.0041","volume":"28","author":"Y Ding","year":"2024","unstructured":"Ding Y, et al. Cadherin 17 nanobody-mediated near-infrared-II fluorescence imaging-guided surgery and immunotoxin delivery for colorectal cancer. Biomater Res. 2024;28:0041.","journal-title":"Biomater Res"},{"issue":"10","key":"3600_CR31","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1172\/JCI128212","volume":"129","author":"MP Labrecque","year":"2019","unstructured":"Labrecque MP, et al. Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. J Clin Invest. 2019;129(10):4492\u2013505.","journal-title":"J Clin Invest"},{"key":"3600_CR32","doi-asserted-by":"publisher","first-page":"104476","DOI":"10.1016\/j.ebiom.2023.104476","volume":"89","author":"X Guo","year":"2023","unstructured":"Guo X, et al. NIR-II fluorescence imaging-guided colorectal cancer surgery targeting CEACAM5 by a nanobody. EBioMedicine. 2023;89:104476.","journal-title":"EBioMedicine"},{"issue":"2","key":"3600_CR33","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.ccell.2019.06.009","volume":"36","author":"W Su","year":"2019","unstructured":"Su W, et al. The polycomb repressor complex 1 drives double-negative prostate cancer metastasis by coordinating stemness and immune suppression. Cancer Cell. 2019;36(2):139-155.e10.","journal-title":"Cancer Cell"},{"issue":"23","key":"3600_CR34","doi-asserted-by":"publisher","first-page":"6916","DOI":"10.1158\/1078-0432.CCR-19-1423","volume":"25","author":"H Beltran","year":"2019","unstructured":"Beltran H, et al. The role of lineage plasticity in prostate cancer therapy resistance. Clin Cancer Res. 2019;25(23):6916\u201324.","journal-title":"Clin Cancer Res"},{"issue":"16","key":"3600_CR35","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s40265-018-1000-9","volume":"78","author":"S Dhillon","year":"2018","unstructured":"Dhillon S. Moxetumomab pasudotox: first global approval. Drugs. 2018;78(16):1763\u20137.","journal-title":"Drugs"},{"issue":"10","key":"3600_CR36","doi-asserted-by":"publisher","first-page":"4575","DOI":"10.1073\/pnas.1820388116","volume":"116","author":"M Onda","year":"2019","unstructured":"Onda M, Kobayashi K, Pastan I. Depletion of regulatory T cells in tumors with an anti-CD25 immunotoxin induces CD8 T cell-mediated systemic antitumor immunity. Proc Natl Acad Sci U S A. 2019;116(10):4575\u201382.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"3600_CR37","first-page":"317","volume":"12","author":"F Zhang","year":"2024","unstructured":"Zhang F, et al. Treatment strategies with combined agency against severe viral pneumonia in patients with advanced cancer. J Transl Int Med. 2024;12(3):317\u201320.","journal-title":"J Transl Int Med"},{"issue":"4","key":"3600_CR38","doi-asserted-by":"publisher","first-page":"pkac043","DOI":"10.1093\/jncics\/pkac043","volume":"6","author":"ND James","year":"2022","unstructured":"James ND, et al. Docetaxel for nonmetastatic prostate cancer: long-term survival outcomes in the STAMPEDE randomized controlled trial. JNCI Cancer Spectr. 2022;6(4):pkac043.","journal-title":"JNCI Cancer Spectr"},{"issue":"11","key":"3600_CR39","doi-asserted-by":"publisher","first-page":"e2340787","DOI":"10.1001\/jamanetworkopen.2023.40787","volume":"6","author":"BA Mahal","year":"2023","unstructured":"Mahal BA, et al. Mortality risk for docetaxel-treated, high-grade prostate cancer with low PSA levels: a meta-analysis. JAMA Netw Open. 2023;6(11):e2340787.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"3600_CR40","doi-asserted-by":"publisher","first-page":"189033","DOI":"10.1016\/j.bbcan.2023.189033","volume":"1879","author":"S Li","year":"2024","unstructured":"Li S, Kang Y, Zeng Y. Targeting tumor and bone microenvironment: novel therapeutic opportunities for castration-resistant prostate cancer patients with bone metastasis. Biochim Biophys Acta Rev Cancer. 2024;1879(1):189033.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"11","key":"3600_CR41","doi-asserted-by":"publisher","first-page":"2846","DOI":"10.1158\/1078-0432.CCR-13-3309","volume":"20","author":"H Beltran","year":"2014","unstructured":"Beltran H, et al. Aggressive variants of castration-resistant prostate cancer. Clin Cancer Res. 2014;20(11):2846\u201350.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"3600_CR42","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1515\/jtim-2024-0019","volume":"12","author":"N Tan","year":"2024","unstructured":"Tan N, et al. Histological transformation in lung adenocarcinoma: Insights of mechanisms and therapeutic windows. J Transl Int Med. 2024;12(5):452\u201365.","journal-title":"J Transl Int Med"},{"issue":"1","key":"3600_CR43","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/s41585-024-00900-z","volume":"22","author":"MK Bakht","year":"2025","unstructured":"Bakht MK, Beltran H. Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer. Nat Rev Urol. 2025;22(1):26\u201345.","journal-title":"Nat Rev Urol"},{"issue":"8","key":"3600_CR44","doi-asserted-by":"publisher","first-page":"7286","DOI":"10.3390\/curroncol30080529","volume":"30","author":"S Hoshi","year":"2023","unstructured":"Hoshi S, et al. PSMA targeted molecular imaging and radioligand therapy for prostate cancer: optimal patient and treatment issues. Curr Oncol. 2023;30(8):7286\u2013302.","journal-title":"Curr Oncol"},{"issue":"9","key":"3600_CR45","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1038\/s41556-021-00743-5","volume":"23","author":"A Davies","year":"2021","unstructured":"Davies A, et al. An androgen receptor switch underlies lineage infidelity in treatment-resistant prostate cancer. Nat Cell Biol. 2021;23(9):1023\u201334.","journal-title":"Nat Cell Biol"},{"issue":"11","key":"3600_CR46","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1093\/oncolo\/oyac161","volume":"27","author":"J Yao","year":"2022","unstructured":"Yao J, et al. DLL3 as an emerging target for the treatment of neuroendocrine neoplasms. Oncologist. 2022;27(11):940\u201351.","journal-title":"Oncologist"},{"issue":"6","key":"3600_CR47","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1080\/14737140.2022.2071703","volume":"22","author":"N Ranallo","year":"2022","unstructured":"Ranallo N, et al. Delta-like ligand 3 (DLL3): an attractive actionable target in tumors with neuroendocrine origin. Expert Rev Anticancer Ther. 2022;22(6):597\u2013603.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"1","key":"3600_CR48","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1186\/s12951-024-02900-y","volume":"22","author":"E Alexander","year":"2024","unstructured":"Alexander E, Leong KW. Discovery of nanobodies: a comprehensive review of their applications and potential over the past five years. J Nanobiotechnology. 2024;22(1):661.","journal-title":"J Nanobiotechnology"},{"issue":"6","key":"3600_CR49","doi-asserted-by":"publisher","first-page":"5994","DOI":"10.3390\/ijms24065994","volume":"24","author":"BK Jin","year":"2023","unstructured":"Jin BK, et al. NANOBODIES\u00ae: a review of diagnostic and therapeutic applications. Int J Mol Sci. 2023;24(6):5994.","journal-title":"Int J Mol Sci"},{"issue":"8","key":"3600_CR50","doi-asserted-by":"publisher","first-page":"e2350773","DOI":"10.1002\/eji.202350773","volume":"54","author":"L Boutin","year":"2024","unstructured":"Boutin L, et al. Camelid-derived Tcell engagers harnessing human \u03b3\u03b4 T cells as promising antitumor immunotherapeutic agents. Eur J Immunol. 2024;54(8):e2350773.","journal-title":"Eur J Immunol"},{"issue":"11","key":"3600_CR51","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.3390\/biom11111696","volume":"11","author":"RJ Kreitman","year":"2021","unstructured":"Kreitman RJ, Pastan I. Immunotoxins: from design to clinical application. Biomolecules. 2021;11(11):1696.","journal-title":"Biomolecules"},{"issue":"10","key":"3600_CR52","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1073\/pnas.1821733116","volume":"116","author":"Z Shancer","year":"2019","unstructured":"Shancer Z, et al. Anti-BCMA immunotoxins produce durable complete remissions in two mouse myeloma models. Proc Natl Acad Sci U S A. 2019;116(10):4592\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"3600_CR53","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.3390\/cancers12061648","volume":"12","author":"AP Masilamani","year":"2020","unstructured":"Masilamani AP, et al. An anti-PSMA immunotoxin reduces Mcl-1 and Bcl2A1 and specifically induces in combination with the BAD-Like BH3 mimetic ABT-737 apoptosis in prostate cancer cells. Cancers (Basel). 2020;12(6):1648.","journal-title":"Cancers (Basel)"},{"issue":"11","key":"3600_CR54","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3390\/toxins10110470","volume":"10","author":"Y Leshem","year":"2018","unstructured":"Leshem Y, et al. SS1P immunotoxin induces markers of immunogenic cell death and enhances the effect of the CTLA-4 blockade in AE17M mouse mesothelioma tumors. Toxins (Basel). 2018;10(11):470.","journal-title":"Toxins (Basel)"},{"issue":"4","key":"3600_CR55","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1080\/0284186X.2019.1704864","volume":"59","author":"Y Andersson","year":"2020","unstructured":"Andersson Y, et al. Immune stimulatory effect of anti-EpCAM immunotoxin - improved overall survival of metastatic colorectal cancer patients. Acta Oncol. 2020;59(4):404\u20139.","journal-title":"Acta Oncol"},{"issue":"550","key":"3600_CR56","doi-asserted-by":"publisher","first-page":"eaaz7252","DOI":"10.1126\/scitranslmed.aaz7252","volume":"12","author":"Q Jiang","year":"2020","unstructured":"Jiang Q, et al. Enhanced efficacy of mesothelin-targeted immunotoxin LMB-100 and anti-PD-1 antibody in patients with mesothelioma and mouse tumor models. Sci Transl Med. 2020;12(550):eaaz7252.","journal-title":"Sci Transl Med"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03600-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-025-03600-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-025-03600-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T14:12:24Z","timestamp":1757254344000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-025-03600-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,18]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3600"],"URL":"https:\/\/doi.org\/10.1186\/s12951-025-03600-x","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,18]]},"assertion":[{"value":"19 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research was approved by the Ethics Committee of the Fifth Affiliated Hospital of Southern Medical University (2024MNWK-K-001), the Shenzhen People\u2019s hospital (AUP-230224-LZJ-543-01) and Nanchang University (BR\/AF\/SG-04\/1.0-202112).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All subjects have written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"525"}}